title: Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?
authors.affiliation: Department of Neurology, Klinikum rechts der Isar, Technische Universität München, München, Germany. florian@castrop.com
authors.forename: F
authors.initials: F
authors.lastname: Castrop
authors.forename: M C
authors.initials: MC
authors.lastname: Kowarik
authors.forename: H
authors.initials: H
authors.lastname: Albrecht
authors.forename: M
authors.initials: M
authors.lastname: Krause
authors.forename: B
authors.initials: B
authors.lastname: Haslinger
authors.forename: C
authors.initials: C
authors.lastname: Zimmer
authors.forename: A
authors.initials: A
authors.lastname: Berthele
authors.forename: B
authors.initials: B
authors.lastname: Hemmer
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001259:Ataxia / Q000209:etiology; D001921:Brain / Q000473:pathology; D005260:Female; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications* / Q000188:drug therapy*; D000069442:Natalizumab; D010951:Plasma Exchange; D011409:Propylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use*; D012008:Recurrence; D013110:Sphingosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013131:Spine / Q000473:pathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D011409:Propylene Glycols; D016899:Interferon-beta; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine; D000068556:Interferon beta-1a